- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05377684
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (ROSE)
March 29, 2024 updated by: Ipsen
Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study
The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor-2 (HER2) negative breast cancer who are receiving, in addition to triptorelin, an endocrine cancer treatment.
The study will also get more information about: - the effectiveness and safety of triptorelin; - the relationship that could exist between the characteristics of the disease and the treatment chosen by the Investigator.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
419
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ipsen Recruitment Enquiries
- Phone Number: See email
- Email: clinical.trials@ipsen.com
Study Locations
-
-
-
Bologna, Italy, 40138
- Recruiting
- Policlinico S. Orsola - Malpighi
-
Cagliari, Italy, 9121
- Not yet recruiting
- Ospedale Oncologico "A. Businco"
-
Firenze, Italy, 50134
- Recruiting
- Azienda Ospedaliero-Universitaria Careggi (Aouc)
-
Lecco, Italy, 23900
- Recruiting
- ASST Lecco
-
Milano, Italy, 20132
- Recruiting
- IRCCS San Raffaele
-
Milano, Italy, 20132
- Recruiting
- Istituto Europeo di Oncologia
-
Milano, Italy, 20133
- Recruiting
- Istituto Nazionale Tumori
-
Napoli, Italy, 80131
- Not yet recruiting
- AORN Cardarelli
-
Napoli, Italy, 80131
- Recruiting
- Istituto Nazionale Tumori - Fondazione Pascale
-
Napoli, Italy, 80138
- Recruiting
- Università della Campania "L. Vanvitelli"
-
Napoli, Italy, 80147
- Recruiting
- P.O. Ospedale del Mare
-
Potenza, Italy, 85100
- Recruiting
- Ospedale San Carlo
-
Pozzuoli, Italy, 80078
- Not yet recruiting
- Ospedale Santa Maria delle Grazie
-
Roma, Italy, 168
- Recruiting
- Policlinico Universitario A. Gemelli (Site A)
-
Roma, Italy, 168
- Recruiting
- Policlinico Universitario A. Gemelli (Site B)
-
Rozzano, Italy
- Recruiting
- Humanitas Cancer Center
-
Torino, Italy
- Recruiting
- Ospedale G. Battista - Molinette
-
Treviglio, Italy, 24047
- Recruiting
- ASST BG OVEST Ospedale di Treviglio
-
Viagrande, Italy, 95029
- Recruiting
- Istituto Oncologico del Mediterraneo (IOM)
-
Vicenza, Italy, 36100
- Not yet recruiting
- Ospedale "S. Bortolo"
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
The study is aimed at premenopausal participants diagnosed with HR-positive and HER2 negative early breast cancer who are starting treatment with triptorelin at the discretion of the treating physician and who consent to participate in the study.
Description
Inclusion Criteria :
- Premenopausal (as per local definition) female patients aged ≥18 years on the day the informed consent is signed;
- Patients have histologically proven, HR-positive and HER2 negative breast cancer according to local definition, determined by immunohistochemistry, and up to stage IIIA. Note: patients with synchronous bilateral breast cancer and patients with breast cancer (BRCA)1/2 gene mutations are eligible;
- Patients have been prescribed adjuvant endocrine treatment with TAM or an AI plus triptorelin (either the 1 month or 3 month formulation) by their treating physician or, in alternative, triptorelin given in combination or consequent to neoadjuvant/adjuvant chemotherapy. Note: the decision to prescribe triptorelin is made by the treating physician prior to and independently of the decision to enroll the patient in this study;
- Patients must be documented to be disease-free at enrolment, as determined by the treating physician according to institutional standards. Note: in case the patient has been prescribed neoadjuvant treatment, the patient will receive surgery and be enrolled but will only remain in the study if disease-free condition is confirmed after surgery. If this condition is not confirmed, then the patient will be discontinued from the study;
- Written informed consent for trial participation must be signed and dated by the patient and the Investigator prior to enrolment;
- Patients have been informed of and agree to data transfer and handling, in accordance with national data protection guidelines;
- Patients must be accessible for follow-up;
- Patients may have received previous treatment with triptorelin for another indication, but the last administration must have occurred at least 6 months before enrolment.
Exclusion Criteria :
- Patient is currently enrolled in any other clinical study or has participated in one within the 12 weeks prior to the Inclusion visit, or is scheduled to receive a new investigational drug while this study is ongoing;
- Patient is not eligible for triptorelin treatment as guided by the product's label in Italy due to safety concerns or has prior history of no responsiveness to triptorelin (in case of previous triptorelin treatment);
- Patient has premenopausal status that cannot be defined;
- Patient has had bilateral oophorectomy or ovarian irradiation;
- Patient has current loco-regional relapse and/or distant metastatic disease;
- Patient has a history of prior (ipsi- and/or contralateral) invasive breast cancer;
- Patient has a history of malignancy other than invasive breast cancer, with the following exceptions: (a) Patients diagnosed, treated and disease-free for at least 5 years and deemed by the Investigator to be at low risk for recurrence of that malignancy are eligible; (b) Patients with the following malignancies are eligible, even if diagnosed and treated within the past 5 years: in situ breast ductal carcinoma; in situ cervical cancer; in situ thyroid cancer; nonmetastatic, no melanomatous skin cancers;
- Patient has concurrent disease or condition that would make study participation inappropriate or any serious medical disorder that would interfere with the patient's safety;
- Patient has psychiatric, addictive, or any other disorder that would prevent compliance with protocol requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants reaching a clinically significant change in the global Quality of Life (QoL) score.
Time Frame: At 18 months.
|
Defined as a minimum change of ≥4 points using the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire.
|
At 18 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor characteristics.
Time Frame: At baseline.
|
At baseline.
|
|
Percentage of days covered of compliance
Time Frame: At 18 months
|
At 18 months
|
|
Description of breast cancer treatment.
Time Frame: At baseline.
|
Including triptorelin formulation (1-month or 3-month formulation), planned neoadjuvant/adjuvant chemotherapy (yes/no) and oral adjuvant endocrine treatment prescribed ((Aromatase Inhibitor (AI) or Tamoxifen (TAM))
|
At baseline.
|
Identification of potential demographic factors predictive of any treatment switch.
Time Frame: At 18 months.
|
A multivariate logistic regression will be used to identify demographic factors predictive of any treatment switches.
|
At 18 months.
|
Identification of demographic and tumor characteristics correlated to the entire prescribed breast cancer treatment.
Time Frame: At 18 months.
|
A multivariate logistic regression will be used to identify characteristics correlated to the prescription of the 1-month or 3-month triptorelin formulations with TAM or an AI.
|
At 18 months.
|
Proportion of participants who switch between triptorelin formulations, from AI to TAM or vice-versa, or undergo both triptorelin and adjuvant therapy switches
Time Frame: At 18 months.
|
The switches between triptorelin formulation or from the AI to TAM will be described together with the reasons for switches.
|
At 18 months.
|
Proportion of disease-free participants.
Time Frame: At 18 months.
|
Disease-free survival is defined as the time from triptorelin initiation to disease recurrence as determined by the Investigator.
|
At 18 months.
|
Proportion of participants alive.
Time Frame: At 18 months.
|
The OS rate will be estimated using the Kaplan-Meier method.
Survival time will be defined as the time from triptorelin initiation to participant's death for any reason.
|
At 18 months.
|
Proportion of compliant patients (100% of the planned injections) to triptorelin
Time Frame: At 18 months.
|
At 18 months.
|
|
Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of suboptimal OFS.
Time Frame: At 18 months.
|
as per local definition, or empirically defined as E2 levels ranging between 30 and 70 pg/ml according to the average range collected in Italian centers.
A multivariate logistic regression will be used to identify predictive factors of suboptimal OFS as per local definition
|
At 18 months.
|
Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of clinically significant global QoL change
Time Frame: At 6, 12 and 18 months.
|
A multivariate logistic regression will be used to identify any predictive factors of clinically significant global QoL change (i.e.
≥4 points).
|
At 6, 12 and 18 months.
|
Incidence of all treatment-emergent adverse events (TEAEs)
Time Frame: From baseline up to 18 months.
|
Summary incidence tables of nonserious and serious AEs, as well as special situations presented overall, by System Organ Class and Preferred term (MedDRA coding) and according to intensity and causality
|
From baseline up to 18 months.
|
Change in the Quality of Life (QoL) score using the FACT-G questionnaire with the Endocrine Symptoms (ES) subscale.
Time Frame: From baseline and at 6, 12 and 18 months
|
All global scores and subscores of the QoL questionnaire will be described at each timepoint.
Comparisons will be performed using the paired Student t-test.
|
From baseline and at 6, 12 and 18 months
|
Description of demographic data.
Time Frame: At baseline.
|
Including age at diagnosis, parity, pregnancy desire (yes/no), oocyte cryopreservation (yes/no) and embryo cryopreservation (yes/no);
|
At baseline.
|
Description of demographic data
Time Frame: At baseline.
|
Including Body Mass Index calculation
|
At baseline.
|
Proportion of participants with hormonal levels (E1, E2 and FSH) corresponding to Ovarian Function Suppression (OFS)
Time Frame: From baseline up to 18 months.
|
As per local definition, or empirically defined as E2 levels <30 pg/ml according to the average level collected in Italian centers)
|
From baseline up to 18 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ipsen Medical, Director, Ipsen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 9, 2022
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
April 29, 2022
First Submitted That Met QC Criteria
May 16, 2022
First Posted (Actual)
May 17, 2022
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-52014-452
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Where patient data can be anonymized, Ipsen will share all individual participant data that underlie the results reported in the published journal article with qualified researchers who provide a valid research question.
Study documents, such as the study protocol and clinical study report, are not always available.
IPD Sharing Time Frame
Data are available beginning 6 months and ending 5 years after the publication of the findings in a journal; after this time, only raw data may be available.
IPD Sharing Access Criteria
Proposals should be submitted to DataSharing@ipsen.com and will be assessed by a scientific review board.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-stage Breast Cancer
-
Dana-Farber Cancer InstituteCompletedEarly Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Jonsson Comprehensive Cancer CenterDaiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.SRecruitingInvasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast CancerUnited States
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Stanford UniversityNational Institutes of Health (NIH); University of California; Breast Cancer... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)United States
-
University of Wisconsin, MadisonNot yet recruitingEarly-stage Breast CancerUnited States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
Rigshospitalet, DenmarkNot yet recruitingEarly-stage Breast Cancer